Ranibizumab biosimilar (Jecho Biopharmaceuticals)

Main study objective To evaluate the clinical equivalence of intravitreal injection of JL14002 monoclonal antibody injection or ranibizumab injection in patients with wAMD. Secondary study objectives 1) To compare the pharmacokinetic characteristics of wAMD patients receiving intravitreal injection of JL14002 monoclonal antibody injection or ranibizumab injection; 2) To compare the safety of wAMD patients receiving intravitreal injection of JL14002 monoclonal antibody injection or ranibizumab injection; 3) To evaluate the safety and tolerability of wAMD patients who cross over to the test drug after receiving ranibizumab injection for 12 weeks and continue to use ranibizumab injection; 4) To evaluate the safety and tolerability of wAMD patients who cross over to the test drug after receiving ranibizumab injection for 12 weeks and continue to use the test drug; 5) To compare the pharmacodynamic characteristics of wAMD patients receiving intravitreal injection of JL14002 monoclonal antibody injection or ranibizumab injection; 6) To compare the immunogenicity of wAMD patients receiving intravitreal injection of JL14002 monoclonal antibody injection or ranibizumab injection.